With a revenue increase of 10.18% in the second quarter 2026, year on year to cumulative value of $30,457 million, Gilead Sciences Inc 's revenue per employee grew on a trailing twelve months basis to $ 1,791,588. The productivity of Gilead Sciences Inc 's employees was 0.0%, above the company average.
Within the Healthcare sector Employees of 40 other companies have achieved higher revenue per employee. While Gilead Sciences Inc 's total ranking has deteriorated compared to the previous quarter from 336 to 493. Gilead Sciences Inc has 17,000 employees.

What is Sales per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Revenue per Employee▼

None ▼

Revenue per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GILD Revenue per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Revenue Change	10.18 %	4.39 %	4.7 %	2.97 %	1.84 %
Sales per Employee (TTM) $	1,791,588	1,749,176	1,731,941	1,711,000	1,697,824
GILD's Total Ranking	# 493	# 336	# 267	# 574	# 436
Seq. Revenue Change	12.11 %	-12.18 %	2.01 %	9.7 %	6.22 %

GILD Company Profile >> Back to GILD Efficiency Comparisons >> Compare GILD Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 6
Healthcare Sector	# 41
Overall Market	# 493

Revenue per Employee Statistics
High	Average	Low
$ 1,931,706	$ 1,079,169	$ 105,219
(Mar 31 2016)		(Sep. 30, 2005)

Financial Statements
Gilead Sciences Inc 's Revenue MRQ	$ 7,803 Millions	Visit GILD's Income Statement
Gilead Sciences Inc 's Revenues TTM	$ 30,457 Millions	Visit GILD's aggregate revenue growth
What are GILD's Sales?		Visit GILD's Sales by Segment

News about Gilead Sciences Inc Revenue per employee

Gilead Sciences Unveils Groundbreaking Antiviral Data and Manufacturing Innovations, Solidifying Its Leadership...

In a pivotal leap for antiviral research and development, Gilead Sciences, Inc. (Nasdaq: GILD) is set to showcase groundbreaking findings at IDWeek 2025, scheduled from October 19-22 in Atlanta, GA. With a comprehensive agenda featuring 34 presentations on the latest advances in HIV, viral hepatitis, respiratory viruses, and other viruses of pandemic potential, Gilead reinforces its status as a leader in the field of antiviral science. Among these, six presentations will be delivered orally, underscoring the company’s commitment to sharing vital data with the global health community.The illuminating research set for presentation at IDWeek highlights not only Gilead’s innovative therapeutic solutions but also illuminates its ongoing dedication to safeguarding public health. The focus will encompass Gilead s efforts to advance treatments in critical health areas, including novel partnerships, research methodologies, and emerging data from clinical trials that underscore the efficacy of its antiviral candidates across diverse populations.

Other Ratios
Gilead Sciences Inc 's Income per Employee
Employees in Biotechnology & Pharmaceuticals
Biotechnology & Pharmaceuticals Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
GILD's Revenue per Employee versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for GILD's Competitors
Revenue per Employee for GILD's Suppliers
Revenue per Employee for GILD's Customers

You may also want to know
GILD's Sales Growth Rates	GILD's Pe Price to earnings ratio	GILD's Receivables Turnover Ratio	GILD's Stock Quote
GILD's Net Income Growth Rates	GILD's Ps Price to Sales ratio	GILD's Sales per Employee	GILD's Asset Turnover Ratio
GILD's Net Margin	GILD's Pb Price to Book ratio	GILD's Financial Strength Ratios	GILD's Dividend Payout Ratio

Date modified: 2026-09-08T15:11:45+00:00

Companies with similar Revenue per Employee for 12 months ending Jun 30 2026, within Healthcare Sector	Revenue per Employee	Revenue 12 months ending Jun 30 2026	Number of Employees Jun 30 2026
Amgen Inc	2,930,384.62	$ 38,095.000 Million	13,000
Innoviva Inc	2,645,471.70	$ 420.630 Million	159
Aurinia Pharmaceuticals Inc	2,433,648.44	$ 311.507 Million	128
Eton Pharmaceuticals Inc	2,392,704.55	$ 105.279 Million	44
Cormedix Inc	2,366,196.28	$ 451.943 Million	191
Sarepta Therapeutics Inc	2,364,483.83	$ 1,974.344 Million	835
United Therapeutics Corporation	2,253,214.29	$ 3,154.500 Million	1,400
Biocryst Pharmaceuticals Inc	2,162,328.74	$ 940.613 Million	435
Elite Pharmaceuticals Inc	2,155,839.86	$ 140.130 Million	65
Protagonist Therapeutics inc	2,136,303.03	$ 281.992 Million	132
Exelixis Inc	2,123,731.47	$ 2,435.920 Million	1,147
Zevra Therapeutics Inc	2,112,377.05	$ 128.855 Million	61
Liquidia Corporation	2,087,532.41	$ 450.907 Million	216
Tg Therapeutics Inc	2,003,849.62	$ 799.536 Million	399
Prestige Consumer Healthcare Inc	1,938,521.05	$ 1,104.957 Million	570
Privia Health Group Inc	1,923,384.18	$ 2,358.069 Million	1,226
Alnylam Pharmaceuticals Inc	1,921,672.80	$ 4,804.182 Million	2,500
Gilead Sciences Inc	1,791,588.24	$ 30,457.000 Million	17,000
Collegium Pharmaceutical Inc	1,777,172.58	$ 751.744 Million	423
Fennec Pharmaceuticals Inc	1,692,028.57	$ 59.221 Million	35
Neurocrine Biosciences Inc	1,686,950.00	$ 3,373.900 Million	2,000
Mirum Pharmaceuticals Inc	1,661,470.43	$ 618.067 Million	372
Tarsus Pharmaceuticals Inc	1,638,732.43	$ 606.331 Million	370
Agenus Inc	1,638,185.19	$ 132.693 Million	81
Xenetic Biosciences Inc	1,630,388.50	$ 3.261 Million	2
Ideaya Biosciences Inc	1,614,668.97	$ 234.127 Million	145
Eli Lilly And Company	1,593,316.00	$ 79,665.800 Million	50,000
Jazz Pharmaceuticals Plc	1,592,122.15	$ 4,601.233 Million	2,890
Rigel Pharmaceuticals Inc	1,590,718.39	$ 276.785 Million	174
Progyny Inc	1,531,890.19	$ 1,311.298 Million	856

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.